AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 217.23B +36.4% |
| Revenue (ttm) | 45.77B +9.9% |
| Net Income | 7.87B +33.7% |
| EPS | 5.03 +33.6% |
| Shares Out | 1.55B |
| PE Ratio | 27.85 |
| Forward PE | 17.67 |
| Dividend | 2.36 (1.69%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 923,814 |
| Average Volume | 2,051,773 |
| Open | 14,106 |
| Previous Close | 14,006 |
| Day's Range | 13,882 - 14,120 |
| 52-Week Range | 10,103 - 15,732 |
| Beta | 0.22 |
| RSI | 48.66 |
| Earnings Date | Apr 29, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsNews
Daiichi Sankyo, AstraZeneca’s Datroway approved in U.S to treat TNBC
Daiichi Sankyo (DSNKY) and AstraZeneca’s (AZN) Datroway has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic triple negative breast cancer who are not…
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/NYSE: AZN) Datroway® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with ...
AstraZeneca and Daiichi Sankyo’s Enhertu recommended in EU by CHMP in HER2
The company states: “AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union as a monotherapy for the treatment of adult...
AstraZeneca’s Camizestrant recommended for approval in EU by CHMP
The company states: “AstraZeneca’s (AZN) camizestrant in combination with a cyclin-dependent kinase 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) has been recommended for approval in the Euro...
AstraZeneca announces new data from portfolio, pipeline at ASCO meeting
AstraZeneca (AZN) announces new data across its portfolio and pipeline at the American Society of Clinical Oncology, ASCO, Annual Meeting, 29 May to 2 June 2026. EMERALD-3: Phase III trial…
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to eliminate cancer as a cause of death and transform outcomes for people living with rare diseases with new data across its divers...
EU regulator recommends positive opinion of AstraZeneca's experimental breast cancer drug
A European Medicines Agency committee said on Friday it has adopted a positive opinion of AstraZeneca's experimental breast cancer drug, camizestrant.
AstraZeneca designates key managerial personnel for materiality determination
AstraZeneca Pharma India has notified the National Stock Exchange of India and BSE Limited of the contact details of Key Managerial Personnel authorised to determine the materiality of events and…
Top 5 FTSE 100 AI Stocks to Watch in 2026: Exposure Across Pharma, Defense and Infrastructure
In 2026, several FTSE 100 companies, including AstraZeneca and Rolls-Royce, are leveraging AI for growth, despite the index's limited direct AI representation. These firms illustrate AI's indirect imp...
AstraZeneca (AZN) Faces Potential Market Shifts Amid Trump's Prescription Plan
AstraZeneca (AZN) Faces Potential Market Shifts Amid Trump's Prescription Plan
AstraZeneca (AZN) Secures FDA Approval for Groundbreaking Treatment
AstraZeneca (AZN) Secures FDA Approval for Groundbreaking Treatment
US Supreme Court rebuffs pharma challenge to Biden-era drug price
The U.S. Supreme Court declined on Monday to hear a pharmaceutical industry challenge to a plan to curb Medicare drug prices adopted during Democratic former President Joe Biden's administration that...
Jefferies says Baxfendy approval may be incrementally constructive for Mineralys
Jefferies analyst Dennis Ding notes that AstraZeneca’s (AZN) Baxfendy was approved by the FDA as the first-ever aldosterone synthase inhibitor, adding that Baxfendy’s approval may be “incrementally co...
The Zacks Analyst Blog Highlights Costco, Coca-Cola, AstraZeneca and Franklin Financial Services
Costco, Coca-Cola, AstraZeneca and Franklin Financial Services are highlighted for resilient growth and strong execution.
AstraZeneca (AZN) Receives US Approval for Innovative Hypertension Treatment
AstraZeneca (AZN) Receives US Approval for Innovative Hypertension Treatment
AstraZeneca (AZN) Secures FDA Approval for Novel Hypertension Treatment
AstraZeneca (AZN) Secures FDA Approval for Novel Hypertension Treatment
AstraZeneca Announces FDA Approval Of BAXFENDY For Hypertension
LONDON (dpa-AFX) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) said BAXFENDY has been approved in the US as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combin...
AstraZeneca, Daiichi Sankyo's ENHERTU Wins FDA Approval In Two Early Breast Cancer Indications
(RTTNews) - AstraZeneca(AZN, AZN.L, ZEG.DE, AZN.ST) and Daiichi Sankyo Company's (4568.T) ENHERTU has been approved by the US Food and Drug Administration (FDA) for both neoadjuvant or use before surg...
AstraZeneca announces U.S. approval for BAXFENDY in hypertension
AstraZeneca’s (AZN) BAXFENDY has been approved in the US as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive medications, to...
AstraZeneca Wins FDA Approval for $5 Billion Blood Pressure Drug
AstraZeneca Wins FDA Approval for $5 Billion Blood Pressure Drug
BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's BAXFENDY™ (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combin...
AstraZeneca’s Baxfendy approved in U.S. for treatment of hypertension
AstraZeneca’s (AZN) Baxfendy has been approved in the US as a first-in-class aldosterone synthase inhibitor, ASI, for the treatment of hypertension in combination with other antihypertensive medicatio...
AstraZeneca (AZN) Gains Approval for New Hypertension Drug Baxfendy
AstraZeneca (AZN) Gains Approval for New Hypertension Drug Baxfendy
‘We Have Been Waiting… for Many Years’: AstraZeneca Stock (AZN) Drops despite Win for Potential Blockbuster Pill
AstraZeneca’s ($AZN) shares edged lower early Monday despite the British pharma giant securing approval for its Baxfendy (baxdrostat) blood pressure pill. The drug is seen as a blockbuster drug candid...
AstraZeneca (AZN) Receives FDA Approval for Baxfendy in Hypertension Treatment
AstraZeneca (AZN) Receives FDA Approval for Baxfendy in Hypertension Treatment